Pharmaceutical Patent Settlements Under Fire on Both Sides of the Atlantic


In recent weeks, the pharmaceutical industry has been in the crosshairs of antitrust enforcers in the U.S. and in Europe. Specifically, patent litigation settlements in which a brand pharmaceutical manufacturer makes a payment to a potential generic entrant in return for a delay of entry (so-called “reverse payment settlements”) are under attack on both sides of the Atlantic.

Please see full update for more information.

LOADING PDF: If there are any problems, click here to download the file.